Hyperuricemia Market

1. Hyperuricemia Market What is Hyperuricemia? Hyperuricemia occurs when there is an excessive amount of acid in your blood. High uric acid levels can cause several diseases, including a painful sort of arthritis called gout. Elevated acid levels also are related to health conditions like heart condition, diabetes, and kidney disease. DelveInsight launched a new report titled "Hyperuricemia Market Report 2030” which delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and market trends within the 7MM. Hyperuricemia Sign & Symptoms Only about one-third of individuals with hyperuricemia experience symptoms referred to as asymptomatic hyperuricemia. Although hyperuricemia isn't a disease, if uric acid levels remain high, over time they will cause several diseases. In another case, uric acid crystals can develop kidney stones. Counting on the dimensions of the kidney stone, symptoms can include severe lower back pain, blood in urine, fever, nausea, and vomiting, foul-smelling urine, stomach aches. Got queries? Click here to read more insights @ Hyperuricemia Market Outlook Hyperuricemia Epidemiology Insights:

2. The Hyperuricemia Epidemiology section of the report includes information on the diagnosed patient pool, trends, and assumptions used. ● According to the report, it's estimated the maximum amount is 21% of the overall population and 25% of hospitalized patients have asymptomatic hyperuricemia. ● According to the survey, when using a common cut-off value hyperuricemia is seen to be twice as common in men as shown in other studies. ● According to the study, the prevalence of hyperuricemia increased with age, with the very best prevalence (36.8%[3.2 million]) among individuals ages 80 years or older. For each of the seven major countries, the Hyperuricemia epidemiology section provides information on historical and present Hyperuricemia patient pools, as well as predicted trends. Read more @ Hyperuricemia Epidemiology Insights Hyperuricemia Market Insights The Hyperuricemia market is estimated to increase to USD XX Million in 2030. The major reason behind the market upsurge is the launch of emerging therapies. Diagnosis and treatment of Hyperuricemia still remain challenging as most of the cases are asymptomatic. Some emerging drugs are LC350189, SAP-001, Verinurad, and major key competitors are Shanton Pharma, LG Chem, AstraZeneca. According to DelveInsight, the Hyperuricemia Market in 7MM is predicted to vary within the study period 2018-2030. Hyperuricemia Emerging Therapy Assessment Key pharma players committed to the development of therapies for Hyperuricemia patients are: 1. Verinurad by AstraZeneca 2. SAP-001 by Shanton 3. LC350189 by LG Chem 4. And others. Verinurad by AstraZeneca Verinurad, a selective URAT1 inhibitor, is under development by AstraZeneca. It is an SLC22A12 protein inhibitor that has demonstrated high potency in inhibiting URAT1 and has shown significant sUA lowering in humans at doses as low as 2.5 mg. SAP-001 by Shanton

3. Shanton is currently actively developing SAP-001 for addressing gout metabolic syndrome. Its drug SAP-001 is a new investigational Uric Acid Transporter 1 (URAT1) inhibitor for the chronic management of hyperuricemia and reduced frequency and severity of gout flare in patients with gout. LC350189 by LG Chem LC350189 by LG Life Sciences is under trial for the management of hyperuricemia in gout patients. LG chem initiated a phase II clinical trial to assess the efficacy and safety of three different doses of LC350189. The Hyperuricemia emerging therapy assessment of the report encloses an in-depth analysis of Hyperuricemia marketed drugs and late-stage pipeline drugs. Visit our repository of reports @ DelveInsight Report Store About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.